Irinotecan Accord (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a pro‑drug that is converted inside cancer cells to SN‑38, an active metabolite that binds to the DNA‑topoisomerase I complex. This prevents the re‑ligation of single‑strand DNA breaks during replication, leading to irreversible DNA damage and cell death.

The prescribed dose of Irinotecan Accord is individualized by the treating oncologist based on factors such as body surface area, liver function, prior chemotherapy exposure, and overall clinical status. No fixed dosing schedule is provided in product literature.

Irinotecan is classified as contraindicated during pregnancy and lactation unless the potential therapeutic benefit outweighs the potential risk to the fetus or infant. Women of child‑bearing potential should use effective contraception during treatment and for a defined period after the last dose.

To place an order, submit an enquiry on the Irinotecan Accord product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, offering a distinct mechanism from fluoropyrimidines or oxaliplatin. Compared with agents like capecitabine, Irinotecan provides a different toxicity profile, notably higher rates of diarrhea and neutropenia, but can be synergistic when combined with other chemotherapies.

Irinotecan Accord should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The product should be kept in its original packaging until preparation for infusion to maintain stability.

Irinotecan Accord is given by intravenous infusion, usually over 30‑90 minutes depending on the protocol. The infusion is performed in a clinical setting by qualified healthcare professionals, with appropriate monitoring for infusion‑related reactions.

The most critical adverse events include severe neutropenia, febrile neutropenia, grade 3‑4 diarrhea, intestinal perforation, and hypersensitivity reactions. Early detection through regular blood counts and patient education on symptoms is essential for prompt management.

Patients with known hypersensitivity to Irinotecan or its excipients, those with uncontrolled infections, severe hepatic impairment, or pre‑existing severe bone‑marrow suppression should not be treated with Irinotecan. Clinical judgment is required for each individual case.